Since 2002, The Myositis Association’s annual research funding program has awarded nearly $8.2 million in research support. We are pleased to announce our 2024 grant awards, funding disease-specific projects in…
Continue Reading
CAR T-cell therapy: A viable option for myositis treatment?
Chimeric antigen receptor T-cell (CAR T-cell) therapy is a process developed to treat certain forms of cancers, especially blood cancers like leukemia and lymphoma. Recently, however, researchers have started exploring…
Continue Reading
More on immune boosting supplements
Our article about immune boosting supplements raised many questions about the effects of herbal products for those who live with myositis. Such products have been heavily promoted in recent years…
Continue Reading
Vamorolone approved by FDA
Recently, the FDA announced the approval of a new drug, vamorolone, as a treatment for Duchenne muscular dystrophy (DMD), a genetic muscle disease that usually affects young boys. Understandably, this…
Continue Reading
ProDERM study results of Octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine
Octapharma announced today the results from the ProDERM study on the efficacy and safety of Octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in…
Continue Reading